Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer

Sponsor
National Cancer Centre, Singapore
Study ID
NCT00702182
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to define the schedule and dose of oral vinorelbine (Navelbine) to be used with erlotinib in non-small cell lung cancer.

Key Dates

Start date
Apr 30, 2008
Status verified
Oct 2012
Primary completion
Apr 30, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Conventional Vinorelbine, Erlotinib
    Escalating doses of vinorelbine on Day 1 and Day 8 of 21 Day cycle; Erlotinib 100 mg OD
  • Experimental: Metronomic Vinorelbine, Erlotinib
    Escalating doses of vinorelbine TIW; erlotinib 100 mg OD

Primary Outcome Measure

Define the recommended dose of oral navelbine with erlotinib [ Time Frame: 3 weeks ]

Related Studies